Clinical medical decision-making of acute aortic intramural hematoma: A non-randomized retrospective case study

J Interv Med. 2020 Jul 9;3(3):132-135. doi: 10.1016/j.jimed.2020.07.005. eCollection 2020 Sep.

Abstract

Objective: This study explored the timing of interventional treatment for acute intramural aortic hematoma (IMH) and the corresponding high-risk factors for its development into local aortic dissection (AD).

Method: This retrospective case study method examined clinical follow-up data of 42 patients with acute IMH between April 2013 and October 2016 from the First Affiliated Hospital of Xi'an Jiaotong University. SPSS 17.0 and PPMS1.5 were used to analyze follow-up data spanning 3-12 months (mean, 7.5 ​± ​3.7 months).

Results: Patients were divided into the conversion group and the hematoma group according to whether they developed AD. Among them, 16 patients (38.1%) developed AD and were treated with thoracic endovascular aortic repair (TEVAR). The remaining patients (61.89%) were treated conservatively. After 1 week, the mean aortic diameter of the conversion versus hematoma group was significantly widened. Hemodynamically unstable patients and those with hematoma to the abdominal aorta extension were more likely to develop AD. Patient outcomes after TEVAR were similar between groups.

Conclusion: Our findings suggest that aortic isthmus diameter ≥3.0 ​cm, hematoma extending to the abdominal aorta, and hemodynamic instability are associated with AD development in acute IMH patents. TEVAR should be considered if hematoma thickening, calcification ingression, ulcer progression, or contrast enhancement within the intramural hematoma is noted beyond 2 weeks after IMH onset.

Keywords: Aortic dissection; Interventional therapy; Intramural aortic hematoma.